[HTML][HTML] Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone
A Russo, C Davoli, C Borrazzo, V Olivadese… - Biomedicines, 2022 - mdpi.com
The hyperinflammatory phase represents the main cause for the clinical worsening of acute
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone
A Russo, C Davoli, C Borrazzo, V Olivadese… - …, 2022 - pubmed.ncbi.nlm.nih.gov
The hyperinflammatory phase represents the main cause for the clinical worsening of acute
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone
A Russo, C Davoli, C Borrazzo, V Olivadese… - 2022 - agris.fao.org
The hyperinflammatory phase represents the main cause for the clinical worsening of acute
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
[HTML][HTML] Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone
A Russo, C Davoli, C Borrazzo, V Olivadese… - …, 2022 - ncbi.nlm.nih.gov
The hyperinflammatory phase represents the main cause for the clinical worsening of acute
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
[PDF][PDF] Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone
A Russo, C Davoli, C Borrazzo, V Olivadese… - Arterial …, 2022 - researchgate.net
The hyperinflammatory phase represents the main cause for the clinical worsening of acute
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone.
A Russo, C Davoli, C Borrazzo, V Olivadese… - …, 2022 - search.ebscohost.com
The hyperinflammatory phase represents the main cause for the clinical worsening of acute
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone
A Russo, C Davoli, C Borrazzo, V Olivadese… - …, 2022 - search.proquest.com
The hyperinflammatory phase represents the main cause for the clinical worsening of acute
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone.
A Russo, C Davoli, C Borrazzo, V Olivadese… - Biomedicines, 2022 - europepmc.org
The hyperinflammatory phase represents the main cause for the clinical worsening of acute
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …